Alerta

A Vaccine Composition of Cells Expressing a Lentiviral Vector and Methods of Using

Resumen de: US20260250717A1

0000 A vector construct is described that is a lentiviral construct including DNA encoding for GM-CSF. A vaccine composition is also described that is includes K562 cells transfected with this vector construct, and also possibly including the U266 and H929. Methods are described for using the vaccine composition in methods of immunizing against plasma cell disorders, including multiple myeloma and related disorders.

Compounds

Resumen de: GB2704209A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein R groups are as defined herein, X-Y is -NHSO2- or -SO2NH; A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; R1 is haloalkyl or OR3; R2 is H or halo; R3 is alkyl or benzyl; and each R4 is independently alkyl or halo. R5 is selected from CO2H, CONHSO2R10, CONR11R12 and tetrazolyl. R6 and R7 are independently H, alkoxy or halo. R8 is selected from halo, alkoxy, haloalkoxy, alkyl, haloalkyl, (CH2)k-cycloalkyl, hydroxyalkyl, CN, OH, SOR9, SO2R9 and heteroaryl. R9 is alkyl, R10 is alkyl, cycloalkyl, aryl or heteroaryl optionally substituted, R11 is H or alkyl, R12 is H, CN, alkyl or CONH2, and k is 0, 1, 2 or 3. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include 3-(N-(2-(cyclobutylamino)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methylbenzoic acid. No Figure

Compounds

Resumen de: GB2704195A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; B is NR6R7, wherein R6 and R7 together with the nitrogen to which they are attached form a 5-, 6- or 7-membered heterocycloalkyl group that is substituted by one or more R5 groups, and is optionally further substituted by one or more R13 groups, optionally wherein two non-adjacent carbons in the heterocycloalkyl group are linked by a one or two carbon alkylene bridge; each R5 is independently selected from (CR1aR1b)aNR8R9, OR10, NR8CO2R11 and NR8COR12. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include (R)(N-(2-(cyclohexylamino)-4-fluoro-5-(trifluoromethyl)phenyl)-3-hydroxypiperidine-1-sulfonamide Formula (I)

Compounds

Resumen de: GB2704140A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein X-Y is -NHSO2-, v is 1 or 2; A is selected from C4-C8-cycloalkyl, fused or bridged bicyclic C6-C12- cycloalkyl, or C4-C8-cycloalkyl fused to an aryl or heteroaryl group, each optionally substituted by one or more R4 groups. R1 is haloalkyl or OR3; R2 is H or halo; R3 is alkyl or benzyl; and each R4 is independently alkyl or halo. R5a is selected from COOH, CONR8R9, CONHSO2R10 and heteroaryl; R5b is H, alkyl or halo. R6a and R6b are each independently H or alkyl, or together form a CO group with the carbon atom to which they are attached. R7a and R7b are each independently H or alkyl, may together form a cycloalkyl group, or R7a is H and R7b and R5b together form a 1- or 2-carbon alkylene bridge. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include (R)-4-(N-(2-(cyclohexylamino)-5-(trifluoromethyl)phenyl)sulfamoyl)morpholine-2-carboxylic acid Formula (I)

Compounds

Resumen de: GB2704162A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein R groups are as defined herein, X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; R1 is haloalkyl or OR3; R2 is H or halo; R3 is alkyl or benzyl; and each R4 is independently alkyl or halo. B is NR6R7, wherein R6 and R7, together with the nitrogen to which they are attached, form a heterocycloalkyl group, wherein said heterocycloalkyl group is fused to at least one saturated cyclic group to form a fused polycyclic group wherein one or more carbons in the fused polycyclic group is optionally replaced by a group indepependetly selected from NR10, CO, N, O, S, SO and SO2, and is optionally further substituted by one or more R5 groups; each R5 is independently selected from NR8R9, OH, alkyl, halo, haloalkyl, alkoxy, and hydroxyalkyl. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include N-(2-(cyclohexylamino)-4-fluoro-5-(trifluoromethyl)phenyl)-2-methyl-3-oxooctahydropyrrolo3,4-cpyridine-5-sulfonamide. No Figure

Compounds

Resumen de: GB2704145A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein R groups are as defined herein, X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; B is a fused bicyclic group selected from the hetero groups as defined herein, the group is further substituted by zero or more R5 groups; each R5 is independently selected from COOH, CONR8R9, CONHSO2R10, SO2R35, NR36R37, alkyl, OH, halo, haloalkyl, alkoxy, and hydroxyalkyl. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include N-(2-(cyclohexylamino)-4-fluoro-5-(trifluoromethyl)phenyl)-5,6-dihydro-1,2,4triazolo1,5-apyrazine-7(8H)-sulfonamide No figure

Compounds

Resumen de: GB2704114A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein X-Y is -NHSO₂-. A is selected from C₄-C₈ cycloalkyl, bicyclic C₅-C₁₂ cycloalkyl, or a C₄-C₈ cycloalkyl fused to an aryl or heteroaryl group, each optionally substituted by one or more R₄ groups. R₁ is haloalkyl or OR₃; R₂ is H or halo; R₃ is alkyl or benzyl; and each R₄ is independently alkyl or halo. B is an azetidine group substituted by (R₅)ₘ, wherein R₅ is independently selected from COOH, (CR₁ₐR1b)ₐNR₆R₇, alkyl, haloalkyl, halo, alkoxy, hydroxyalkyl, cycloalkyl, heteroaryl or heterocycloalkyl, optionally substituted. R1a and R1b are independently H, OH, alkyl or hydroxyalkyl; a is 0-3; R₆ and R₇ are independently H, alkyl, SO-alkyl, haloalkyl or heterocycloalkyl; and m is 0-6. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions comprising such cells are also disclosed. Exemplified compounds include N-(2-(cyclohexylamino)-4-fluoro-5-(trifluoromethyl)phenyl)-3-(pyridin-4-yl)azetidine-1-sulfonamide. Formula (I)

Compounds

Resumen de: GB2704272A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; B is NR6R7, wherein R6 and R7 together with the nitrogen to which they are attached form a 5 to 8-membered heterocycloalkyl group containing at least one further group selected from NR38, CO, SO2 and SONH, optionally wherein two non-adjacent carbons in the heterocycloalkyl group are linked by a one or two carbon alkylene bridge or an ether bridge, and wherein the said hetrocycloalkyl group is optionally substituted by one or more groups selected from R5 and R35, R5 is selected from COOH, CONR8R9, CONHSO2R10, tetrazolyl and hydroxyalkyl; R38 is selected from H, alkyl and CO-alkyl. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include 4-(N-(2-(cyclohexylamino)-5-(trifluoromethyl)phenyl)sulfamoyl)-1-methylpiperazine-2-carboxylic acid Formula (I)

Compounds

Resumen de: GB2704197A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; B is NR6R7, wherein R6 and R7 together with the nitrogen to which they are attached form a 5 to 7-membered heterocycloalkyl group optionally containing one or more further groups selected from S, SO and SO2, optionally wherein two non-adjacent carbons in the heterocycloalkyl group are linked by a one or two carbon alkylene bridge, and wherein the said hetrocycloalkyl group is substituted by one or more R5 groups, and is optionally further substituted by one or more R35 groups; R5 is selected from (CR1aR1b)aCOOH, CONR8R9, CONHSO2R10, SO(N=H)-R10 and tetrazolyl. Rxx groups are as defined herein. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include (S)-1-(N-(2-(cyclohexylamino)-5-(trifluoromethyl)phenyl)sulfamoyl)piperidine-3-carboxylic acid. Formula (I)

MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE

Resumen de: AU2025227271A1

This application pertains to the use of Compound (A): or a pharmaceutically acceptable salt thereof, for the treatment of various diseases or disorders, including, for example, advanced non-Hodgkin lymphoma (NHL), relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), transformed follicular lymphoma, nodal T-follicular helper cell lymphoma (nTFHL), relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma, nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL- Al) / advanced angioimmunoblastic T-cell lymphoma (AITL), or relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL-AI) / angioimmunoblastic T-cell lymphoma (AITL).

NANOBODIES AND NANOBODY-BASED CARS AND METHODS OF USING THE SAME TO TARGET BLOOD CANCERS

Resumen de: WO2026173613A2

The present disclosure provides nanobodies that specifically target blood cancer antigens such as TIM-3, CLEC12a, BCMA, CD38, CD229, SLAMF7, and BAFF-R, and methods of using the same to treat blood cancers such as AML and multiple myeloma. The present disclosure also provides engineered immune cells comprising nanobody-based chimeric antigen receptors (CARs) that include nanobodies that specifically target blood cancer antigens such as TIM-3, CLEC12a, BCMA, CD38, CD229, SLAMF7, and BAFF-R, and methods of using the same to treat blood cancers such as AML and multiple myeloma.

OTUD7A INHIBITOR COMPOUNDS AND METHODS

Resumen de: WO2026174182A1

Pyrazolopyrimidines and imidazopyrazine compounds of Formulas (I) and (II) are provided. The compounds can be used to target OTU domain-containing protein 7A (OTUD7A), e.g., to block and/or reduce OTUD7A-mediated deubiquitination of Ewing sarcoma breakpoint region 1-Friend leukemia virus integration 1 transcription factor (EWS-FLI1). Methods of treating conditions dependent on FLI1, including Ewing sarcoma, leukemia, and other cancers, by administering the compounds, are also described.

PHARMACEUTICAL COMPOSITION COMPRISING PIPERIDINE RING COMPOUND, AND USE THEREOF

Resumen de: WO2026171195A1

The present invention provides a pharmaceutical composition comprising a piperidine ring compound, and a use thereof. Specifically provided is a pharmaceutical composition, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof and CHOP or CHOEP. The pharmaceutical composition provided by the present invention has synergistic advantages, and has good therapeutic efficacy against lymphoma.

ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF

Resumen de: WO2026174042A1

Provided are compounds of the structural Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.

ANTIMALARIAL ENDOPEROXIDE DERIVATIVES FOR THE TREATMENT OF MYELODYPLASTIC SYNDROME

Resumen de: US20260242391A1

Disclosed herein are methods for using an antimalarial endoperoxide compound, such as artemisinin, intreating a subject suffering from myelodysplastic syndromes (MDS), and in slowing or preventing the progression of MDS in the subject to development of acute myeloid leukemia (AML).

Methods of Treating High Risk Multiple Myeloma

Resumen de: US20260242503A1

Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

Bispecific anti-CD28 x anti-CD22 antibodies and uses thereof

Resumen de: AU2026210818A1

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen- binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen- binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial. ul u l

DENOSUMAB FORMULATION

Resumen de: US20260242496A1

0000 An aqueous pharmaceutical formulation having improved stability includes denosumab and a poloxamer, and preferably a histidine buffer and/or sugar or sugar alcohol. The formulation is for use in treating or preventing osteoporosis, loss of bone mass, skeletal-related events associated with multiple myeloma, solid tumor bone metastases, giant cell tumors of the bone or hypercalcemia.

USE OF ANTI-CD20 ANTIBODY DRUG CONJUGATE IN PREPARATION OF DRUG FOR TREATING NON-HODGKIN LYMPHOMA

Resumen de: US20260241027A1

0000 The present disclosure discloses a use of anti-CD20 ADC in the preparation of a drug for treating NHL, and the drug has excellent clinical efficacy and safety in treating a R/R NHL patient after receiving at least two standard treatments.

CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING FL1-1 EXPRESSION

Resumen de: US20260241033A1

The present disclosure is directed to CRISPR-related systems and components for targeting, editing, and/or modulating expression of a FLI-1 (Friend virus leukemia integration 1 transcription factor; Fli-1 Proto-Oncogene, ETS Transcription Factor) gene. The present disclosure also relates to methods and applications thereof in connection with engineered cells including T cells or T cell precursors.

COMPOSITIONS FOR TREATMENT OF CANCER AND USES THEREOF

Resumen de: WO2026174057A1

The present disclosure provides for compositions comprising a combination of marine biomass extracts for use in the treatment of cancer, where the cancer is a leukemia, a bladder cancer, a gastric cancer, a breast cancer, a multiple myeloma, a lung cancer, or a pancreatic cancer. Further provided herein are biomass compositions having extracts from Holothuria scabra, Holothuria nobilis, Heliocidaris erythrogramma, Styela clava, and Sargassum pallidum. Moreover, in such compositions the majority components may be extracts from sea cucumber.

Compounds

Resumen de: GB2704112A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein R groups are as defined herein, X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; R1 is haloalkyl or OR3; R2 is H or halo; R3 is alkyl or benzyl; and each R4 is independently alkyl or halo. B is NR6R7, wherein R6 and R7 are linked to form a polycyclic group containing at least one spiro carbon, and which polycyclic group optionally contains one or more groups independently selected from NR35, CO, O, S, SO and SO2, and is optionally further substituted by one or more R5 groups; each R5 is independently selected from COOH, CONR8R9, CONHSO2R10, NR30R31, CO2-alkyl, OH, alkyl, halo, haloalkyl, alkoxy, aminoalkyl, and hydroxyalkyl. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include N-(2-(cyclohexylamino)-5-(trifluoromethyl)phenyl)-2,4-dioxo-1,3,7-triazaspiro4,5decane-7-sulfonamide No Figure

METHODS FOR PREDICTING RESPONSIVENESS OF LYMPHOMA TO DRUG AND METHODS FOR TREATING LYMPHOMA

Resumen de: WO2025080543A1

Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.

METHODS FOR TREATING MULTIPLE MYELOMA COMPRISING AN ANTI-CD38 ANTIBODY COMBINED WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE

Resumen de: WO2025080911A1

The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.

ANTI-VISTA ANTIBODIES AND FRAGMENTS

Nº publicación: US20260234264A1 13/08/2026

Solicitante:

JANSSEN PHARMACEUTICA NV [BE]
JANSSEN PHARMACEUTICA NV

Resumen de: US20260234264A1

The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.